Maze Therapeutics (NASDAQ:MAZE) Trading 5.6% Higher – Still a Buy?

Maze Therapeutics, Inc. (NASDAQ:MAZE)’s stock price rose 5.6% on Tuesday . The company traded as high as $11.98 and last traded at $11.43. Approximately 44,124 shares traded hands during trading, a decline of 87% from the average daily volume of 339,422 shares. The stock had previously closed at $10.82.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. JPMorgan Chase & Co. assumed coverage on Maze Therapeutics in a report on Tuesday. They set an “overweight” rating and a $30.00 target price on the stock. Leerink Partners began coverage on Maze Therapeutics in a research note on Tuesday. They issued an “outperform” rating and a $28.00 price objective for the company. Finally, Guggenheim began coverage on Maze Therapeutics in a report on Tuesday. They issued a “buy” rating and a $19.00 target price on the stock.

Maze Therapeutics Stock Up 2.5 %

Maze Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.